Effects of hormonal contraceptives on dry eye disease: A population-based study

Paper Presentation | Présentation d'article
4:00 PM, samedi 26 juin 2021 (5 minutes)

Authors: Bonnie He, Alfonso Iovieno, Mahyar Etminan, Abbas Kezouh, Sonia Yeung.

Disclosure Block: B. He: None. A. Iovieno: None. M. Etminan: None. A. Kezouh: None. S. Yeung: None.

Abstract Title: Effects of Hormonal Contraceptives on Dry Eye Disease: A Population-Based Study

Abstract Body:

Purpose: To investigate associations between hormone contraceptives (HCs) and dry eye disease (DED) in women of child-bearing age.

Study Design: This was a retrospective case-control study of a cohort of 4,871,504 women (age 15-45) between 2008 to 2018.

Methods: Data was obtained from the IQIVA Ambulatory EMR database (IQVIA, USA). DED cases were defined as those with a first ICD-9 (375.15) or ICD-10 (H04.121, H04.122, H04.123, H04.129) code, and at least two prescriptions of cyclosporine or lifitegrast topical drops within 60 days of the first code. The date of the first code was designated as the index date. For each case, five controls were selected using density-based sampling and matched to the cases by age and follow-up time. Regular contraceptive users had at least two prescriptions in both the first year and second year prior to the index date, and those who used at least one prescription in days 0-90 or days 91-365 prior to the index date were further subdivided into current or past use, respectively. Irregular contraceptive users included anyone who did not meet the criteria for regular use. The HCs included were combined oral contraceptives, intrauterine levonorgestrel, medroxyprogesterone injection and etonogestrel vaginal ring. A conditional logistic regression model was used to calculate rate ratios (RRs) and adjust for confounders of DED. All RRs were compared to subjects with no HCs use.

Results: 1,799 DED cases and 7,196 controls were included in the study. Regular users of HCs were more likely to develop DED (RR = 2.73, 95%CI [2.21-3.73]) than irregular users (RR = 1.80, 95%CI [1.58-2.04]). The risk for developing DED also increased with greater number of HCs used, with a RR of 1.66 (95% CI [1.42-1.94]) among women who used 1-2 HCs, and a RR of 2.16 (95% CI [1.74-2.69]) for those who used 3-4 HCs. Women who used more than four HCs were at greatest risk, with a RR of 2.35 (95% CI [1.98-2.79]).

Conclusions: This is the largest study to date that has found an increased risk of DED with HCs use in females of reproductive age. Physicians prescribing HCs should discuss the risk of DED with their patients when reviewing the side effect profile. More studies are needed to confirm the associations observed and elucidate whether different dosages or formulations of HCs impart a greater risk for DED.

Detail de session
Pour chaque session, permet aux participants d'écrire un court texte de feedback qui sera envoyé à l'organisateur. Ce texte n'est pas envoyé aux présentateurs.
Afin de respecter les règles de gestion des données privées, cette option affiche uniquement les profils des personnes qui ont accepté de partager leur profil publiquement.